Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Activated Glucocorticoid Receptor is an Estrogen Receptor Silencer in ERα+ metastatic breast cancer.

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE286892 | GEO | 2025/10/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Activated Glucocorticoid Receptor is an Estrogen Receptor Silencer in ERα+ metastatic breast cancer [ChIP-seq]

Project description:Estrogen Receptor alpha (ERα)-positive, HER2-negative breast cancers are less aggressive than other subtypes and generally show good patient clinical outcome because they are likely to respond to endocrine therapies. Unfortunately, therapy-resistant metastases may develop and start an inexorable downhill course. ESR1 mutations leading to ligand-independent ERa activation and resistance to endocrine therapy are prevalent in 20 - 55% of patients with ER+ metastatic breast cancer. Here, we found that glucocorticoid receptor (GR) activation by dexamethasone in ESR1 mutant metastases-bearing mice decreases liver metastases, enhances chemotherapy responsiveness, and prolongs survival. Transcriptomic profiling and proteomics profiling revealed that GR activation not only downregulates estrogen reponse signature but also induces dramatic loss of ER itself, therefore uncovering an estrogen receptor silencing action of GR. ChIP-Seq analysis revealed that prolonged Dex treatment almost completely abrogates ER chromatin binding and that GR binds a subset of ER-related genes including ESR1 itself. This was accompanied by loss of H3K27 acetylation and enhancer acetylation, hence inhibiting transcription. Finally, we found that GR activation in patient-derived organoids reduces the number of ER+ cancer cells and ERα abundance, and predicts good outcome in patients with ER+ breast cancer, using publicly available data. These data imply that administration of synthetic glucocorticoids reduces ER+ cell proliferation, inhibits metastatic ability, enhances chemotherapy efficacy and hence can be beneficial for patients with ER+ metastatic breast cancer, particularly the treatment of refractory ESR1 mutant metastases.

2025-10-15 | GSE286891 | GEO

Activated Glucocorticoid Receptor is an Estrogen Receptor Silencer in ERα+ metastatic breast cancer [RNA-seq]

2025-10-15 | GSE286890 | GEO

Activated Glucocorticoid Receptor is an Estrogen Receptor Silencer in ERα+ metastatic breast cancer.

Project description:Activated Glucocorticoid Receptor is an Estrogen Receptor Silencer in ERα+ metastatic breast cancer.

| PRJNA1210499 | ENA